Literature DB >> 22083413

The diagnosis and treatment of thyroid-associated ophthalmopathy.

Daniel J Gould1, Forrest S Roth, Charles N S Soparkar.   

Abstract

BACKGROUND: Little is written in the plastic surgery literature about thyroid-associated ophthalmopathy (TAO), a condition that is separate from Graves-Basedow disease and may not be accompanied by hyperthyroidism. Many patients with this disease frequently seek periocular aesthetic reconstruction prior to medical workup.
METHODS: This study presents a comprehensive review of the literature surrounding TAO in order to better understand the prevalence, diagnosis, pathophysiology, and appropriate management of TAO.
RESULTS: TAO is frequently under- or misdiagnosed by health-care providers. Patients seeking blepharoplasty or other oculoplastic procedures may have underlying TAO, and the prevalence of TAO in patients who have had a blepharoplasty is approximately 3%. This condition occurs five times more often in women than in men. As a product of the relatively high prevalence of this disease and its underdiagnosis, TAO patients may experience perioperative and late complications due to surgery.
CONCLUSION: Blepharoplasties performed on TAO patients must be undertaken with care and insight to avoid cosmetic and functional complications.

Entities:  

Mesh:

Year:  2011        PMID: 22083413     DOI: 10.1007/s00266-011-9843-4

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  9 in total

1.  Biomarker identification of thyroid associated ophthalmopathy using microarray data.

Authors:  Hong-Bin Yang; Jie Jiang; Lu-Lu Li; Huang-Qiang Yang; Xiao-Yu Zhang
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

2.  Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues.

Authors:  Hao Hu; Xiao-Quan Xu; Lu Chen; Wen Chen; Qian Wu; Huan-Huan Chen; Hui Zhu; Hai-Bin Shi; Fei-Yun Wu
Journal:  Endocrine       Date:  2020-06-05       Impact factor: 3.633

3.  Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).

Authors:  Raymond S Douglas; Tünde Mester; Anna Ginter; Denise S Kim
Journal:  Trans Am Ophthalmol Soc       Date:  2014

4.  Radiological Staging of Thyroid-Associated Ophthalmopathy: Comparison of T1 Mapping with Conventional MRI.

Authors:  Lu Chen; Wen Chen; Huan-Huan Chen; Qian Wu; Xiao-Quan Xu; Hao Hu; Fei-Yun Wu
Journal:  Int J Endocrinol       Date:  2020-10-22       Impact factor: 3.257

5.  Usefulness of two-point Dixon T2-weighted imaging in thyroid-associated ophthalmopathy: comparison with conventional fat saturation imaging in fat suppression quality and staging performance.

Authors:  Lu Chen; Hao Hu; Huan-Huan Chen; Wen Chen; Qian Wu; Fei-Yun Wu; Xiao-Quan Xu
Journal:  Br J Radiol       Date:  2020-12-22       Impact factor: 3.039

6.  T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy.

Authors:  Linhan Zhai; Qiuxia Wang; Ping Liu; Ban Luo; Gang Yuan; Jing Zhang
Journal:  Korean J Radiol       Date:  2022-04-26       Impact factor: 7.109

7.  Preliminary study of abnormalities in saccade dynamics in patients with hyperthyroidism with no pre-existing eye damage.

Authors:  Yan Sun; Xinhui Xie; Yongxia Xu; Chen Wang; Xiaoming Kong
Journal:  Exp Ther Med       Date:  2020-01-17       Impact factor: 2.447

8.  3-D cephalometry of the the orbit regarding endocrine orbitopathy, exophthalmos, and sex.

Authors:  Konstantin Volker Hierl; Matthias Krause; Daniel Kruber; Ina Sterker
Journal:  PLoS One       Date:  2022-03-11       Impact factor: 3.240

9.  Disrupted Spontaneous Neural Activity in Patients With Thyroid-Associated Ophthalmopathy: A Resting-State fMRI Study Using Amplitude of Low-Frequency Fluctuation.

Authors:  Wen Chen; Qian Wu; Lu Chen; Jiang Zhou; Huan-Huan Chen; Xiao-Quan Xu; Hao Hu; Fei-Yun Wu
Journal:  Front Hum Neurosci       Date:  2021-06-11       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.